Axsome Therapeutics
AXSM
65 hedge funds and large institutions have $216M invested in Axsome Therapeutics in 2019 Q1 according to their latest regulatory filings, with 38 funds opening new positions, 13 increasing their positions, 9 reducing their positions, and 8 closing their positions.
1,899% more capital invested
Capital invested by funds: $10.8M → $216M (+$205M)
375% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 8
189% more call options, than puts
Call options by funds: $25.4M | Put options by funds: $8.8M
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
86% more funds holding
Funds holding: 35 → 65 (+30)
44% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 9
31.69% more ownership
Funds ownership: 12.84% → 44.53% (+32%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$30.6M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
+$11.1M |
| 3 |
VMI
VHCP Management III
New York
|
+$9.92M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$9.75M |
| 5 |
RI
RTW Investments
New York
|
+$5.53M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Sio Capital Management
New York
|
-$3.14M |
| 2 |
ECM
Endurant Capital Management
San Mateo,
California
|
-$1.46M |
| 3 |
RA
Royce & Associates
New York
|
-$1.39M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$705K |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$208K |
AXSM Hedge Fund Activity: Q1 2019 in Review
65 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Axsome Therapeutics (AXSM) for Q1 2019, worth a combined $216M — up 1,899% from $10.8M a quarter earlier.
Buyers outnumbered sellers: 38 funds opened new AXSM positions and 8 closed out — a net gain of 30 holders — while 13 added to existing stakes and 9 trimmed.
The largest buyer was RA Capital Management, opening a new position worth an estimated $30.6M. The largest seller was Sio Capital Management, cutting an estimated $3.14M.
- 65 institutional investors held Axsome Therapeutics (AXSM) as of Q1 2019, up from 35 in Q4 2018.
- Funds reported $216M of Axsome Therapeutics stock for Q1 2019, up 1,899% quarter-over-quarter.
- 38 funds opened new Axsome Therapeutics positions in Q1 2019 and 8 closed out, a net change of +30 holders.
- The largest Axsome Therapeutics buyer in Q1 2019 was RA Capital Management, an estimated $30.6M added.
- The largest Axsome Therapeutics seller in Q1 2019 was Sio Capital Management, an estimated $3.14M sold.
Based on aggregated 13F filings for Q1 2019.